Loading clinical trials...
Loading clinical trials...
The purpose of this study is to predict response to Erbitux as a single agent in patients with metastatic colon cancer
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Eli Lilly and Company
NCT06149481 · Metastatic Colorectal Cancer
NCT07446322 · Ras-mutated Metastatic Colorectal Cancer, mCRC, and more
NCT07536113 · Metastatic Colorectal Cancer (CRC)
NCT06820463 · Metastatic Colorectal Cancer
NCT07416552 · Metastatic Colorectal Cancer
Local Institution
Duarte, California
Local Institution
Tampa, Florida
Local Institution
Baltimore, Maryland
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions